Rheumatology

SAN DIEGO — Reducing use of accepted surgical and pharmacological interventions in favor of diet and exercise may be the way forward in osteoarthritis, according to a presentation at the 2019 Congress of Clinical Rheumatology West.

SAN DIEGO — While encouraging patients with cutaneous lupus erythematosus to use adequate sun protection, rheumatologists should be treating disease flares with more potent steroids then tapering off once other therapies are in progress, according to a presentation at the 2019 Congress of Clinical Rheumatology West.

SAN DIEGO — Early screening and early diagnosis are critical to managing systemic sclerosis, according to a presentation at the 2019 Congress of Clinical Rheumatology West.

SAN DIEGO — Although “lupus headache” remains a disease-related entity in the Systemic Lupus Erythematosus Disease Activity Index, debate persists over the lack of a detailed definition for this type of headache and whether it represents a neuropsychiatric symptom of lupus, according to a presentation at the 2019 Congress of Clinical Rheumatology West.

SAN DIEGO — Contrary to previous findings, the risk for psoriatic arthritis was persistent among patients with psoriasis and did not wane over time, according to a presentation at the 2019 Congress of Clinical Rheumatology West.

IBI303, a biosimilar to adalimumab developed by Chinese biopharmaceutical company Innovent Biologics, is comparable in safety and efficacy to the originator drug among patients with ankylosing spondylitis, according to data published in The Lancet Rheumatology.

The FDA has granted Gazyva breakthrough therapy designation for the treatment of adult patients with lupus nephritis, according to a Genentech press release.

GRAND RAPIDS, Mich. — As infusion centers have grown in complexity throughout the years, so too has the patient experience in these suites, with individuals often asked to take on a greater understanding of the clinical and financial impacts of their treatment, according to a presenter at the National Organization of Rheumatology Managers Annual Conference.

Infusion reaction rates to rituximab may be more significant among patients with systemic lupus erythematosus than other diseases, according to findings published in BMC Rheumatology.

GRAND RAPDIS, Mich. — Successful management in rheumatology practices requires both evidence-based approaches and critical thinking, in order to turn complex health care problems into practical solutions, according to a presenter at the 2019 National Organization of Rheumatology Managers Annual Conference.